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Introduction
Arthritic diseases are characterized by a progressive loss
of extracellular matrix (ECM), which may ultimately lead to
frank tissue loss and gross joint damage. The conditions
under which chondrocytes can be induced to replenish or
repair a depleted matrix (and thereby prevent or slow the
disease process) remain unclear. If these conditions were
known, then in principal one could design a therapeutic
strategy that takes into account the capacity (or absence
thereof) for chondrocytes to repair their matrix naturally.
A number of model systems have provided some insights.
For instance, IL-1-degraded cartilage tissues and cell
suspensions are frequently employed as model systems to
study cartilage metabolism under osteoarthritis-like condi-
tions [1–4] and to assess the efficacy of various drug
dGEMRIC = delayed gadolinium enhanced magnetic resonance imaging of cartilage; ECM = extracellular matrix; GAG = glycosaminoglycan; IL =
interleukin; NMR = nuclear magnetic resonance.
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Abstract
In the present study we examined cartilage matrix repair
following IL-1-induced matrix depletion. Previous data indicated
that, in some cases, chondrocytes can synthesize
macromolecules to establish a functional extracellular matrix in
response to a matrix-damaging insult or when placed in a three-
dimensional environment with inadequate matrix. However, the
conditions under which such ‘repair’ can occur are not entirely
clear. Prior studies have shown that chondrocytes in trypsin-
depleted young bovine articular cartilage can replenish tissue
glycosaminoglycan (GAG) and that the rate of replenishment is
relatively uniform throughout the tissue, suggesting that all
chondrocytes have similar capacity for repair. In the present
study we used the characteristic heterogeneous distribution of
matrix depletion in response to IL-1 exposure in order to
investigate whether the severity of depletion influenced the rate
of GAG replenishment. We used the delayed Gadolinium-
Enhanced Magnetic Resonance Imaging of Cartilage
(dGEMRIC) method to monitor the spatial and temporal
evolution of tissue GAG concentration ([GAG]). For both mild
(n=4) and moderate (n=10) IL-1-induced GAG depletion, we
observed partial recovery of GAG (80% and 50% of baseline
values, respectively) over a 3-week recovery period. During the
first 2 weeks of recovery, [GAG] increased homogeneously at
10–15mg/ml per week. However, during the third week the
regions most severely depleted following IL-1 exposure showed
negligible [GAG] accumulation, whereas those regions affected
the least by IL-1 demonstrated the greatest accumulation. This
finding could suggest that the most severely degraded regions
do not recover fully, possibly because of more severe collagen
damage; this possibility requires further examination.
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therapies [5–9]. IL-1 signals cells via cell surface recep-
tors to upregulate proteases, matrix metalloproteinases
and aggrecanase, while downregulating matrix metallopro-
teinase inhibition and proteoglycan synthesis [10,11]. The
ultimate effect of these metabolic changes include
damage to the ECM, loss of ECM components (especially
proteoglycan), and alteration of the normal balance of
catabolic and anabolic processes that regulate cartilage
ECM composition.
With regard to the repair phase, following IL-1-induced
cartilage damage, relatively little is known, but partial to
complete recovery appears possible [1,3]. In studies of
repair, investigators focused on glycosaminoglycan (GAG)
– an important and abundant cartilage macromolecule –
and used histologic, biochemical, and/or radiolabel incor-
poration methods to measure GAG concentration
([GAG]) and/or GAG synthesis rates at selected time
points. Although these data suggest that repair might be
possible, our understanding is limited because of the
uncertainty in the temporal changes in matrix composition
for a given sample. This uncertainty is a direct conse-
quence of the inherently destructive nature of histologic
and biochemical methods; these techniques therefore do
not permit monitoring of the spatial and temporal evolution
of matrix macromolecules within individual samples/
animals. Having to infer temporal spatial information from a
cross-section of samples confounds efforts to conduct a
detailed analysis of responses in these model systems.
The delayed Gadolinium-Enhanced Magnetic Resonance
Imaging of Cartilage (dGEMRIC) method overcomes
these problems in that it is nondestructive and can be
used to assess quantitatively the spatial distribution of car-
tilage [GAG] [12,13]. We and others previously reported
on the use of dGEMRIC to monitor GAG regeneration in
living cartilage tissue over time in trypsin-depleted bovine
cartilage [14] and in cell-laden polymer matrices (tissue
engineered cartilage) [15]. Those studies clearly demon-
strated that dGEMRIC is feasible for long-term [GAG]
monitoring, and that its sensitivity is sufficient to permit
observation of the spatiotemporal evolution of [GAG].
Each of those studies began with a homogeneously pro-
teoglycan-deficient matrix, in which GAG was replenished
over a 5- to 8-week period to levels considered to be
within the normal range.
In young bovine articular cartilage (a tissue that many
investigators have used to investigate the impact of physi-
cal and biochemical factors on ECM metabolism
[14,16–21]), IL-1 induces a characteristic spatially hetero-
geneous depletion of GAG. This young tissue still con-
tains blood vessels, and it is in the perivascular regions
that IL-1-induced GAG depletion is most severe. We
know from studies investigating the recovery of trypsin-
induced homogeneous GAG depletion in young bovine
cartilage that the inherent ability of chondrocytes to
replenish the matrix is relatively uniform [14]. In the
present study, we take advantage of the characteristic
spatial heterogeneity of IL-1-induced GAG depletion to
study the relative replenishment rates between regions of
varying severity of GAG depletion. Accordingly, our goal
was to use dGEMRIC to determine whether bovine carti-
lage explants briefly exposed to IL-1 would recover GAG
at a uniform rate, or at a rate that depended on the degree
of IL-1-induced GAG depletion. Specifically, we sought to
examine recovery after relatively mild and modest degrada-
tion – conditions that did not induce a complete loss of
tissue GAG.
Method
Culture and degradation protocols
Cartilage–bone cores of 5mm or 7mm in diameter were
harvested from young bovine femoropatellar groove articu-
lar cartilage within 24hours of slaughter. After removing
the articular surface, three or four 1-mm-thick discs were
sliced parallel to the articular surface. A flat edge was
made on some of the discs to ease orientation and regis-
tration during imaging and analysis. The discs were
weighed, and then immediately placed in 2ml sterile
culture media in 24-well culture plates. All explants were
incubated at 37°C throughout the study.
Culture medium was prepared with low-glucose Dulbecco’s
modified Eagle medium with 10mmol/l HEPES (GIBCO
BRL, Grand Island, NY, USA), 0.1mmol/l nonessential
amino acids (Sigma Chemical, St. Louis, MO, USA),
0.4mmol/l L-proline (Sigma Chemical), and 1mmol/l
gadolinium-DTPA (Magnevist, Berlex Imaging, Wayne, NJ,
USA). Supplements including: 1% fetal calf serum
(GIBCO BRL, Grand Island, NY), 1% l-glutamine (Sigma
Chemical), 1% ascorbic acid (Sigma Chemical) and 1%
penicillin and streptomycin (Sigma Chemical) were added
immediately prior to use. Media was was collected daily
and analyzed for GAG release by the dimethylmethylene
blue (DMMB) assay using purified shark chondroitin
sulfate (Sigma Chemical) as the reference standard.
All samples were cultured in basal media for at least
3 days after harvest. To create samples that have hetero-
geneously-degraded ECM, samples were exposed to
IL-1β (Cistron Biotechnology, Pine Brooks, NJ, USA),
which was added each day to the culture medium. Two
series of experiments were conducted, each with its own
set of controls. In the first series, samples were exposed
to 10ng/ml IL-1 for 3 and 6 days (incurring ‘mild’ degrada-
tion; n=4). The addition of IL-1 to the media began at
days 6 and 3, respectively, after harvest, such that all
samples began the ‘recovery phase’ on day 9 after
harvest. Control samples were cultured in basal media for
the entire experiment. In the second series, samples were
exposed to 20ng/ml IL-1 (n=10) for 6 and 9 days andR99
incurred ‘moderate’ degradation. In this group the addition
of IL-1 addition to the media for all samples started at
3 days after harvest, and therefore samples began the
recovery phase at day 9 or 12 after harvest. Again, control
samples were cultured in basal media for the entire experi-
ment. Control samples are referred to as ‘mild controls’ or
‘moderate controls’, according to the IL-1 series with
which they were cultured (n=2 and 2).
Following IL-1 exposure, the samples were transferred to
sterile flat-bottomed 10mm nuclear magnetic resonance
(NMR) tubes (Wilbur Scientific, Boston, MA, USA) that were
custom cut to a length of 5cm, where they were cultured in
basal media for the duration of the recovery experiment.
In summary, the experiment comprised three periods: an
initial period (before any exposure to IL-1), an exposure
period (during which tissue was exposed to IL-1 in prepa-
ration for the recovery phase), followed by a recovery
period (during which there was no IL-1 present).
Imaging protocols
For imaging, the shortened NMR/culture tubes were
joined to full-length NMR tubes via a sterilized rubber
stopper inserted into the open ends of both tubes.
All images were acquired on a Bruker 8.45 T magnetic
resonance microimaging system (Bruker Instruments, Bil-
lerica, MA, USA) with a standard 10mm radiofrequency
coil. T1-weighted images in the axial orientation with
respect to explant cylindrical geometry were measured
weekly post-IL-1 exposure with either an inversion recov-
ery sequence (‘mild’ series) or a saturation recovery
sequence (‘moderate’ series). The saturation recovery pro-
tocol consisted of 10 T1-weighted images measured with
time-to-repeat times of 25, 75, 125, 175, 275, 375, 475,
600, 900, and 1800ms. For inversion recovery measure-
ments, images were acquired with nine inversion delays of
16.7, 33.3, 50, 66.7, 100, 150, 250, 400, and 600ms.
Both pulse sequences used a time-to-echo of 8.5ms,
section thicknesses of 0.5mm, in-plane resolutions of
100µm, and two averages, for a total imaging time of less
than 1hour per sample.
Analysis of GAG release throughout these experiments
suggested that, within the range of sensitivity provided by
our dimethylmethylene blue assay, GAG release patterns
were unaffected by removal from incubation at 37°C to
room temperature for 3–6 hours of imaging each week
(because all the plugs were out of the incubator for the
imaging session).
Tissue T1s without contrast agent were determined spec-
troscopically using an inversion delay pulse sequence with
12 delays ranging from 0.2 to 10s and a 10mm broad-
band radiofrequency probe. At the conclusion of each
experimental series, two samples (one control and one
treated) were equilibrated in gadolinium-free medium, then
extracted from media and blotted dry, and placed in an
NMR tube. As had previously been observed, we found
very little difference in T1 between samples of the same
series (<5%) or across series (<10%) [12]. Therefore, the
T1 times in the absence of contrast agent of samples from
the same series were averaged and these averages used
as the reference tissue T1 for all other samples within the
same experiment series.
Image processing
MATLAB (The Math Works, Natick, MA, USA) was used
to create a T1 map by curve-fitting each T1-weighted
image series on a voxel-by-voxel basis. T1 maps were then
processed into GAG maps with MATLAB using equations
derived from a modified ideal Donnan theory. This
dGEMRIC method of relating measured T1 and cartilage
[GAG] was previously validated and reported [12,13,22].
The mean [GAG] for a sample at a given time point was
computed as the mean [GAG] calculated across all carti-
lage-containing pixels of the image. The rate of [GAG]
accumulation (i.e. the tissue’s recovery rate) was calcu-
lated as the difference in the mean [GAG] values at speci-
fied time points divided by the elapsed time.
As expected, qualitative assessment of images from
samples exposed to IL-1 exhibited the characteristic het-
erogeneity in degree of GAG depletion. In order to quanti-
tate objectively the time course of GAG recovery relative
to the degree of GAG depletion, GAG maps were regis-
tered using Adobe Photoshop (Adobe Systems, Inc, San
Jose, CA, USA) in order to allow chosen regions of inter-
est to be automatically analyzed across multiple images
from successive imaging sessions. Registered images
were segmented so that tissue regions of relatively high,
medium, or low [GAG] were identified in images taken
after 3 weeks of recovery. The [GAG] and location of
these pixels were tracked in time. High, medium, and low
[GAG] regions of the 3-week images were discerned
according to the following definitions:
Pixel assigned to ‘high’ GAG region if:
[GAG]pixel > (mean [GAG]all pixels + 0.5 × SDall pixels)
Pixel assigned to ‘low’ GAG region if:
[GAG]pixel < (mean [GAG]all pixels – 0.5 × SDall pixels)
Pixel assigned to ‘medium’ GAG region if not assigned to
high or low region
Statistical analysis
Magnetic resonance imaging derived group mean [GAG]
changes were assessed using repeated-measures one-
way analysis of variance with a compound symmetry vari-
Available online http://arthritis-research.com/content/5/2/R97ance structure using SAS (SAS Institute Inc., Cary, NC,
USA) to test the hypothesis that mean [GAG] in a given
sample or regions of a given sample did not change with
time. This technique analyzed the significance of time as
an effect on weekly [GAG] measurements (or weekly
changes in [GAG]) taken from the same samples (or same
region of a sample) each week. Paired two-sample Stu-
dent’s t-tests (Microsoft Excel) were used to determine the
degree of [GAG] recovery observed with respect to initial
[GAG], before exposure to IL-1.
Results
Glycosaminoglycan release into media
The release of GAG into the media was measured daily as
a surrogate for monitoring the effect of IL-1 exposure and
of ECM stability following IL-1 withdrawal. Control
samples from each series had a small rate of release
throughout (0.4±0.2µg/mg initial wet-weight/day), except
for a slightly higher release rate (0.7±0.2µg/mg initial
wet-weight/day) during the first 2–3 days after harvest.
Assuming an initial [GAG] of approximately 5% of wet-
weight, this steady-state release rate corresponds to a
loss of about 0.6–1%/day.
As expected, during the IL-1 exposure period the exposed
samples lost significantly more GAG than did controls, in
accordance with the severity of the IL-1 exposure. Those
in the ‘mild’ and ‘moderate’ groups lost 148±49µg and
433±98µg GAG, respectively, as compared with the
81±5µg and 103±58µg lost during the same period by
the control samples. The GAG release rates never
dropped to negligible levels during the exposure period,
indicating that GAG was not totally depleted from the
disks at these exposure levels. Turning to the recovery
period, within 1–2 days after cessation of IL-1 exposure
the GAG release rates dropped to levels comparable with
those of control samples. GAG release persisted at this
level (0.3±0.1 and 0.5±0.3µg/mg initial wet-weight/day
for ‘mild’ and ‘moderate’ groups, respectively) throughout
the remainder of the study.
Tissue glycosaminoglycan concentration over time
Use of dGEMRIC allowed for the actual [GAG] in the
tissue to be followed over time. The images of the control
samples showed relatively stable [GAG] over the culture
period (Fig.1a, c), with the coefficient of variation
(SD/mean over time) for ‘bulk’ GAG (i.e. GAG averaged
over the entire cartilage image slice) ranging from 2% to
12%. One can also see that the bulk [GAG] was consid-
erably different for the ‘mild’ and ‘moderate’ control
samples. This is probably a reflection of differences
between the animals used for each series, a conclusion
supported by considering measurements made before
IL-1 exposure on a subset of samples (92±11mg/ml for
the ‘mild’ series and 57±6mg/ml for the ‘moderate’
series; n=6 for each). To provide a relative reference, the
mean and SD of untreated samples are represented by
the shaded regions in Fig.2a, b.
Images of the exposed samples acquired immediately fol-
lowing cessation of IL-1 revealed a much lower [GAG]
than the initial values, and the [GAG] in exposed samples
increased with time of recovery (Figs1 and 2). Over the
3-week recovery period following IL-1 exposure, [GAG]
increased in all samples exposed to IL-1 (Fig.1b, d and
Fig.2, n=14; P<0.0001). In the ‘mild’ group the [GAG]
increased by 19±5mg/ml (n=4; P=0.06) whereas in the
‘moderate’ group [GAG] increased by 26±11mg/ml
(n=10; P<0.0001).
Given the variation in initial [GAG], we evaluated the per-
centage degree of recovery only for those samples for
which we obtained an ‘initial’ image before any exposure to
IL-1 (n=4 ‘mild’ and n=4 ‘moderate’). In these cases the
[GAG] after 3 weeks of recovery did not reach the initial
levels. The [GAG] in the ‘mild’ group reached 77±19% of
initial [GAG] (n=4; P=0.019) and the ‘moderate’ group
reached 49±11% of initial [GAG] (n=4; P=0.00003).
Regional analysis of glycosaminoglycan concentration
recovery
The mean rate of [GAG] recovery (increase in
[GAG]/time) averaged across all pixels of IL-1-degraded
samples remained steady throughout 3 weeks of post-
IL-1-exposure culture at a rate of 1–2mg/ml per day
(1.2±0.9mg/ml per day). However, looking specifically at
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Figure 1
Representative glycosaminoglycan (GAG) map series derived from T1
maps measured on successive weeks. Initial GAG concentration
([GAG]) was substantially different for the two animals (one
animal/series), and therefore each series is shown on its own color-
scale. (A and C) Control [GAG] is stable (COV varied by±2–12%)
throughout the recovery period for both series. (B and D) At the
beginning of the recovery period (week 0), [GAG] for IL-1-exposed
samples is lower than the initial [GAG] and steadily increases over the
3-week recovery period.the spatial distribution of [GAG], considerable differences
in weekly [GAG] recovery are clearly evident across differ-
ent regions of the same samples.
In both the ‘mild’ and ‘moderate’ groups, heterogeneous
degradation patterns prevailed, with greatest degradation
occurring in perivascular regions (Fig.1c, d), although the
degradation in the ‘moderate’ group was more severe and
homogeneous than in the ‘mild’ group (the control images
and abundant experience with this model system supports
the implicit assumption here that the initial [before IL-1]
distribution of GAG was homogeneous).
From a qualitative examination of the recovery images, it
can also be appreciated that the regions with relatively low
[GAG] after 3 weeks are also the regions that had rela-
tively low [GAG] at the beginning of the recovery period,
immediately after IL-1 exposure (Figs1 and 3).
To examine this observation more quantitatively and to
assess whether the rates of GAG accumulation were cor-
respondingly heterogeneous, we examined separately the
[GAG] accumulation in three ‘regions’, namely those with
‘high’, ‘medium’ and ‘low’ [GAG] at week 3 (as specified
above, under Image processing), which is illustrated for
one sample in Fig.3a. Interestingly, regions of ‘low’ [GAG]
appeared to recover at the same rate as did regions of
‘medium’ or ‘high’ [GAG] during the first 2 weeks of post-
IL-1-exposure culture. In the first 2 weeks of recovery, all
regions recovered at a rate of 10–15mg/ml per week.
During the third week the recovery patterns for the three
regions differed significantly (P<0.001), with the ‘low’
regions showing negligible [GAG] accumulation and the
‘high’ regions the greatest accumulation (Fig.3a, c).
Discussion
The present study clearly demonstrates that bovine carti-
lage explants can, at least partially, recover from IL-1-
induced degradation by synthesizing new GAG but that
the ultimate rate of recovery may be dependent on the
degree of initial depletion. By monitoring the spatially
localized changes in [GAG] over a 3-week recovery
period, we showed that [GAG] increases significantly with
time in post-IL-1-exposure culture, with the early recovery
(first 2 weeks) being independent of absolute [GAG] but
the later recovery (third week) occurring only in regions
with higher [GAG].
With respect to the spatial heterogeneity in recovery rates,
we are not aware of any histologic (or other) data describ-
ing the apparent dependence of the rate of [GAG] replen-
ishment on the initial state of the ECM. We previously
showed that spontaneous recovery from complete trypsin-
induced GAG loss occurs uniformly throughout the tissue,
showing no significant spatial heterogeneity in recovery
rates and nearly complete recovery to the initial state in
approximately 5 weeks [14]. Those data suggest that the
capacity for cells to synthesize new matrix is uniform
throughout the tissue. Thus, the differential response seen
here is presumably due to the state of the ECM immedi-
ately after IL-1 exposure.
Here, we consider [GAG] as a surrogate for defining the
ECM state immediately following IL-1 exposure. [GAG]
itself is one direct measure of ECM state. In the context of
the present study, [GAG] might also serve as a surrogate
for the state of other ECM macromolecules, such as colla-
gen. Given the broad spectrum of IL-1-induced enzymes,
we consider that regions of the tissue where [GAG] is
Available online http://arthritis-research.com/content/5/2/R97
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Figure 2
Mean glycosaminoglycan concentration ([GAG]) in IL-1-exposed samples measured at weekly intervals using delayed gadolinium enhanced
magnetic resonance imaging of cartilage (dGEMRIC). The mean [GAG] increase with recovery time for samples subjected to (A) mild (3 and
6 days of 10ng/ml IL-1, n=4; P=0.06) or (B) moderate (6 and 9 days of 20ng/ml IL-1, n=10; P=0.0001) degradation, and then permitted to
recover for 3 weeks in culture. The mean [GAG] for a given sample at a given time point was computed as the mean of [GAG] measured across all
pixels of the image; error bars are±SD between sample means. Shaded regions represent initial [GAG]; 92±11mg/ml for ‘mild’ series and
57±6mg/ml for ‘moderate’ series.more severely affected by IL-1 may also be regions that
experience greater damage to the collagen network, as
compared with regions that are more resistant to the
effects of IL-1. Our finding that the regions that experi-
enced the least recovery were those most severely
affected by IL-1 could be a consequence of these same
regions sustaining more significant damage to the ECM
network. This conclusion is consistent with findings
regarding IL-1-induced degradation in rabbits, in which
recovery rates decreased with apparent severity of degra-
dation [1].
Interestingly, it is in the latter phase of recovery that a dis-
crepancy in recovery rates becomes evident. During the
early phases of recovery, the rate of [GAG] accumulation
in the regions with the lowest [GAG] was comparable to
the rates of recovery in regions with the highest [GAG].
The mechanism for this heterogeneity is unclear. It could
be a manifestation of a corresponding distribution of IL-1-
induced changes in chondrocyte metabolism or viability
[23], or it could be a manifestation of a corresponding dis-
tribution of damage to the collagen scaffold, which in turn
limits the ability to replenish [GAG]. Kruijsen et al. [24]
showed that both the severity and chronicity of antigen-
induced inflammation determined the degree of chondro-
cyte killing in their in vivo murine model of arthritis. Their
studies showed that chondrocyte death was most highly
correlated with the degree of joint inflammation present
14 days after arthritis induction. That finding suggests that
sustained exposure to IL-1, a proinflammatory agent, may
also cause chondrocyte death. However, the fact that the
early recovery phase in the present study showed no het-
erogeneity makes cell death a less likely cause of limited
[GAG] replenishment.
A limitation (and obvious next step) to this study is that we
do not have independent information about the integrity of
the collagen matrix. Magnetic resonance imaging tech-
niques are actively being developed to image the collagen
component of tissue, which can be incorporated into
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Figure 3
(A) Example of regional analysis scheme. For samples in the ‘moderate’ group, glycosaminoglycan concentration ([GAG]) maps measured after
3 weeks of recovery were segmented into ‘low’, ‘medium’, and ‘high’ regions, as specified in the Methods section under Image processing (so that
the set of pixels defined as ‘low’ represented the regions of tissue that recovered the least during the 3-week recovery period and the set defined
as ‘high’ represented tissue that recovered the most). The mean [GAG] of these three regions were followed in time. At each time point,
segmented images were analyzed separately to assess whether GAG contents and recovery rates were comparable. (B) Weekly mean
[GAG]±SD of regions defined as ‘low’ (red), ‘medium’ (yellow), or ‘high’ (green), according to the process illustrated in panel A. (C) Weekly
changes in mean [GAG]±SD are shown for each region. Rate of [GAG] recovery is independent of absolute [GAG] for the first 2 weeks of culture
after IL-1 exposure. ‘Low’, ‘medium’, and ‘high’ GAG regions recover at statistically different rates during the third week following IL-1 exposure
(*P<0.0001). All mean [GAG] values and recovery rates are derived from a total of 10 samples.future studies [25]. Human osteoarthritic tissue is, by his-
tologic measures, spatially heterogeneous in both colla-
gen damage and degree of proteoglycan depletion. The
notion that the differential ability to replenish GAG fully is
related to the differential state of the collagen matrix has
been suggested by others, based in part on the finding that
GAG depletion corresponds with regions that are positive
for the col3/4 epitope, which is indicative of collagen
damage [6,26]. Although we lack specific information on
the state of the collagen matrix, the differences observed in
the present study (and, indeed, the demonstrated ability to
evaluate regional differences in response) suggest that
dGEMRIC and model systems such as these may be
useful for establishing a better understanding of the capac-
ity of cartilage to repair osteoarthritis-like degradation.
The rate of GAG replenishment observed in this study
compares well with published synthesis data. Using
sulfate incorporation over periods of less than 24 hours,
we and others have reported sulfate incorporation ratios
between 0.06 and 0.13nmol/mg wet-weight/hour for
young bovine cartilage [27–29]. These incorporation rates
imply GAG synthesis rates of 6–13mg/ml tissue water
per week (assuming 1 sulfate per disaccharide, 502g/mol
disaccaride, and 0.8ml tissue water/g wet-weight). By
comparison, we observed GAG accumulation rates of
4–14mg/ml per week, as inferred from the change in
[GAG]. These values also compare well with the
2–7.3mg/ml per week rates of GAG replenishment seen in
young bovine cartilage explants recovering from trypsin-
induced GAG depletion [14]. Comparison of these GAG
accumulation rates with the rate of GAG release into the
culture medium clearly suggests that at least 75% of the
newly synthesized GAG is retained by the tissue. (By con-
trast, in control tissue the amount of GAG synthesized is
roughly equivalent to the amount released into the medium.)
We do not have the ability to determine the regional varia-
tions in synthesis and loss. Although we clearly observed
regional variations in [GAG] accumulation, it is important
to appreciate that these differences could arise by
regional differences in synthesis or in loss, or both.
Looking more generally at attempts to evaluate [GAG]
recovery in IL-1-degraded cartilage, our data are consis-
tent with the temporal progression seen in other model
systems in which recovery occurs and is measurable
within the first few weeks after a [GAG]-depleting inter-
vention. For example, Takegami et al. [9] reported [GAG]
recovery in alginate cultures of human intervertebral disc
cells pre-exposed to 0.5ng/ml IL-1 for 3 days. During the
first 2 weeks of post-IL-1-exposure culture, those investi-
gators observed [GAG] recovery rates of approximately
4%/day with very little change in [GAG] observed during
the third week, when [GAG] levels reached about 85% of
the control level. In an in vivo rabbit knee joint subjected to
intra-articular injections of IL-1, Page Thomas et al. [3]
used SO4 uptake and toluidine blue staining to observe
GAG losses of 25–60% in several cartilage sites within
the knee, with gradual recovery over the subsequent
3–4 weeks. Arner [1] also examined in vivo GAG synthe-
sis and accumulation in rabbits following intra-articular
injections of IL-1. Using dimethylmethylene blue assay and
sulfate incorporation, Arner found that both single and
multiple injections of IL-1 led to an initial depression in
GAG synthesis rate and a slight drop in tissue [GAG] for
4 days after IL-1 exposure. These changes were followed
by enhanced synthesis (relative to controls), with a com-
mensurate increase in tissue [GAG] over the subsequent
2 weeks as the content of GAG in the tissue approached
90% of control levels. In those in vivo systems it appears
that GAG loss continues for 4–7 days after IL-1 exposure
[1]. This is longer than the 1–2 days seen in the present
study (in which GAG loss into the medium returned to
control levels), and is probably a consequence of IL-1
clearing more quickly from the in vitro environment.
Thus, in widely different model systems – including that
reported here – it appears that after an IL-1-induced
GAG-depleting intervention tissue can reaccumulate
GAG and does so most rapidly during the first few weeks.
However, unlike the study described here, in which both
spatial and temporal changes in [GAG] were monitored, in
the studies described above it was not possible to derive
more specific spatial information because the destructive
nature of the [GAG] measurements required that time
course information be inferred from averages of separate
animals/samples harvested at different time points.
Our data can also be compared with those from other
studies in which magnetic resonance methods were used
to monitor changes in cartilage tissue during culture. Our
group previously observed spatially uniform recovery of
explants following trypsin-induced GAG depletion using
dGEMRIC, with the increases in [GAG] occurring most
rapidly during the first week and slowing considerably
after 3 weeks [14]. Williams et al. [15] used the same
method to monitor GAG accumulation in tissue engi-
neered cartilage over 6 weeks, and observed relatively
steady GAG accumulation over the entire period, with the
bulk of the accumulation occurring at the periphery of the
explant. The initial state of the cell/polymer construct was
presumably uniform, and the heterogeneous [GAG] accu-
mulation was attributed to differences in the biophysical
environment. Potter et al. [30] observed the growth of
tissue engineered over a period of 4 weeks using proton
NMR without any additional contrast agent. The relative
changes in T1 and T2 times of those studies tracked the
histologic finding that GAG increased for the first 3 weeks
and then remained relatively constant. Collectively, those
studies and the present one illustrate spatial and temporal
variations in GAG accumulation in native, treated, and
Available online http://arthritis-research.com/content/5/2/R97
R103tissue engineered cartilage. Much work, of course,
remains if we are to begin to understand the biochemical,
biophysical, and structural factors that underlie the differ-
ential behavior. Furthermore, much work remains to deter-
mine the generalizability of the behavior in these model
systems involving young tissue to behavior of cartilage
in vivo in older humans.
Conclusion
In the present study we demonstrated that chondrocytes,
in a matrix degraded by IL-1 exposure, partially replen-
ished the GAG, and the most severely degraded regions
replenished less fully than did other regions. Future
studies are underway to examine whether heterogeneity in
replenishment rate is seen in human osteoarthritic tissue.
The study provides additional evidence that the in vitro
dGEMRIC method is a practical means for studying GAG
homeostasis and events that disturb it. Ultimately, such
studies provide the foundation for evaluating the effects of
therapeutic interventions on [GAG] degradation or regen-
eration in vitro or in vivo [13].
Competing interests
None declared.
Acknowledgements
The authors gratefully acknowledge the generous MATLAB coding
assistance of Joseph Samosky. Funding was provided in part by the
NIH, grant #AR42773; NIH Shared Instrumentation, grant #RR14792;
and the Edwin Hood Taplin professorship.
References
1. Arner EC: Effect of animal age and chronicity of interleukin-1
exposure on cartilage proteoglycan depletion in vivo. J Orthop
Res 1994, 12:321-330.
2. Beekman B, Verzijl N, de Roos JA, TeKoppele JM: Matrix degra-
dation by chondrocytes cultured in alginate: IL-1 beta induces
proteoglycan degradation and proMMP synthesis but does
not result in collagen degradation. Osteoarthritis Cartilage
1998, 6:330-340.
3. Page Thomas DP, King B, Stephens T, Dingle JT: In vivo studies
of cartilage regeneration after damage induced by
catabolin/interleukin-1. Ann Rheum Dis 1991, 50:75-80.
4. Patwari P, Kurz B, Sandy JD, Grodzinsky AJ: Mannosamine
inhibits aggrecanase-mediated changes in the physical prop-
erties and biochemical composition of articular cartilage. Arch
Biochem Biophys 2000, 374:79-85.
5. Badger AM, Cook MN, Swift BA, Newman-Tarr TM, Gowen M,
Lark M: Inhibition of interleukin-1-induced proteoglycan
degradation and nitric oxide production in bovine articular
cartilage/chondrocyte cultures by the natural product,
hymenialdisine. J Pharmacol Exp Ther 1999, 290:587-593.
6. Billinghurst RC, Wu W, Ionescu M, Reiner A, Dahlberg L, Chen J,
van Wart H, Poole AR: Comparison of the degradation of type
II collagen and proteoglycan in nasal and articular cartilages
induced by interleukin-1 and the selective inhibition of type II
collagen cleavage by collagenase. Arthritis Rheum 2000, 43:
664-672.
7. McCarty MF, Russell AL: Niacinamide therapy for osteoarthri-
tis: does it inhibit nitric oxide synthase induction by inter-
leukin 1 in chondrocytes? Med Hypotheses 1999, 53:350-360.
8. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F,
Geng C, Pelletier JP: Chondroprotective effect of intraarticular
injections of interleukin-1 receptor antagonist in experimental
osteoarthritis. Suppression of collagenase-1 expression.
Arthritis Rheum 1996, 39:1535-1544.
9. Takegami K, Masuda K, An H, Kamada H, Peitryla D, Thonar I: The
effect of osteogenic protein-1 on intervertebral disc cells pre-
exposed to interleukin-1. In: 46th Annual Meeting Proceedings
of the Orthopaedic Research Society. Transactions of the
Orthopaedic Research Society, Orlando, FL. March 12–15, 2000,
Volume 25, page 338.
10. Smith RL: Degradative enzymes in osteoarthritis. Front Biosci
1999, 4:D704-712.
11. Malemud C, Hering T: Regulation of the chondrocytes in
osteoarthritis. In Biological Regulation of the Chondrocytes.
Edited by Adolphe M. Boca Raton: CRC Press, Inc; 1992:295-320.
12. Bashir A, Gray ML, Burstein D: Gd-DTPA2- as a measure of car-
tilage degradation. Magn Reson Med 1996, 36:665-673.
13. Bashir A, Gray ML, Hartke J, Burstein D: Nondestructive imaging
of human cartilage glycosaminoglycan concentration by MRI.
Magn Reson Med 1999, 41:857-865.
14. Allen RG, Burstein D, Gray ML: Monitoring glycosaminoglycan
replenishment in cartilage explants with gadolinium-
enhanced magnetic resonance imaging. J Orthop Res 1999,
17:430-436.
15. Williams S, Obradovic B, Burstien D, Freed L, Gray M, Langer R,
Vunjak-Novakovic G: MRI measurements of fixed charge
density as a measure of glycosminoglycan content and distri-
bution in tissue engineered cartilage. In: 44th Annual Meeting
Proceedings, Orthopaedic Research Society. Transactions of the
Orthopaedic Research Society, New Orleans, LA. March 16–19,
1998, Volume 23, page 203.
16. Bonassar LJ, Grodzinsky AJ, Frank EH, Davila SG, Bhaktav NR,
Trippel SB: The effect of dynamic compression on the
response of articular cartilage to insulin-like growth factor-I. J
Orthop Res 2001, 19:11-17.
17. Ragan PM, Badger AM, Cook M, Chin VI, Gowen M, Grodzinsky
AJ, Lark MW: Down-regulation of chondrocyte aggrecan and
type-II collagen gene expression correlates with increases in
static compression magnitude and duration. J Orthop Res
1999, 17:836-842.
18. Larsen NE, Lombard KM, Parent EG, Balazs EA: Effect of hylan
on cartilage and chondrocyte cultures. J Orthop Res 1992, 10:
23-32.
19. Sah RL, Kim YJ, Doong JY, Grodzinsky AJ, Plaas AH, Sandy JD:
Biosynthetic response of cartilage explants to dynamic com-
pression. J Orthop Res 1989, 7:619-636.
20. Schafer SJ, Luyten FP, Yanagishita M, Reddi AH: Proteoglycan
metabolism is age related and modulated by isoforms of
platelet-derived growth factor in bovine articular cartilage
explant cultures. Arch Biochem Biophys 1993, 302:431-438.
21. Luyten FP, Yu YM, Yanagishita M, Vukicevic S, Hammonds RG,
Reddi AH: Natural bovine osteogenin and recombinant human
bone morphogenetic protein-2B are equipotent in the mainte-
nance of proteoglycans in bovine articular cartilage explant
cultures. J Biol Chem 1992, 267:3691-3695.
22. Bashir A, Gray ML, Boutin RD, Burstein D: Glycosaminoglycan
in articular cartilage: in vivo assessment with delayed
Gd(DTPA)(2-)-enhanced MR imaging. Radiology 1997,  205:
551-558.
23. Nerucci F, Fioravanti A, Cicero MR, Collodel G, Marcolongo R:
Effects of chondroitin sulfate and interleukin-1beta on human
chondrocyte cultures exposed to pressurization: a biochemi-
cal and morphological study. Osteoarthritis Cartilage 2000, 8:
279-287.
24. Kruijsen MW, van den Berg WB, van de Putte LB: Influence of
the severity and duration of murine antigen-induced arthritis
on cartilage proteoglycan synthesis and chondrocyte death.
Arthritis Rheum 1985, 28:813-819.
25. Gray ML, Burstein D, Xia Y: Biochemical (and functional)
imaging of articular cartilage. Semin Musculoskelet Radiol
2001, 5:329-343.
26. Hollander AP, Pidoux I, Reiner A, Rorabeck C, Bourne R, Poole
AR:  Damage to type II collagen in aging and osteoarthritis
starts at the articular surface, originates around chondro-
cytes, and extends into the cartilage with progressive degen-
eration. J Clin Invest 1995, 96:2859-2869.
27. Sah R-Y: Biophysical Regulation of Matrix Synthesis, Assembly,
and Degradation in Dynamically Compressed Calf Cartilage.
Cambridge, MA: Massachusetts Institute of Technology; 1990.
28. Hascall VC, Handley CJ, McQuillan DJ, Hascall GK, Robinson
HC, Lowther DA: The effect of serum on biosynthesis of pro-
Arthritis Research & Therapy    Vol 5 No 2 Williams et al.
R104teoglycans by bovine articular cartilage in culture. Arch
Biochem Biophys 1983, 224:206-223.
29. Boustany NN, Gray ML, Black AC, Hunziker EB: Correlation
between synthetic activity and glycosaminoglycan concentra-
tion in epiphyseal cartilage raises questions about the regula-
tory role of interstitial pH. J Orthop Res 1995, 13:733-739.
30. Potter K, Butler JJ, Adams C, Fishbein KW, McFarland EW,
Horton WE, Spencer RG: Cartilage formation in a hollow fiber
bioreactor studied by proton magnetic resonance microscopy.
Matrix Biol 1998, 17:513-523.
Correspondence
ML Gray, Massachusetts Institute of Technology, Harvard–MIT Division
of Health Sciences and Technology, 45 Carleton Street, E25-519,
Cambridge, MA 02142, USA. Tel: +1 617 258 8974; fax: +1 617 253
7498; e-mail: mgray@mit.edu
Available online http://arthritis-research.com/content/5/2/R97
R105